What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with aranesp therapy (treat)?: No smoking gun

Circulation

Volumn 124, Issue 25, 2011, Pages 2805-2808

  Winkelmayer, Wolfgang C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; HEART INFARCTION; HEMODIALYSIS; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANEMIA; DIABETES MELLITUS, TYPE 2; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC; STROKE;

EID: 84055190056     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.071985     Document Type: Review

References (9)

1. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000. (Pubitemid 20034923)
2. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590. (Pubitemid 28385655)
3. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-2084. (Pubitemid 44749316)
4. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098. (Pubitemid 44749317)
5. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032.
6. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJV, Singh AK, Solomon SD, Uno H, Pfeffer M.A. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darboetin alfa: the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) experience. Circulation. 2011;124:2903-2908.
7. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer M.A. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146-1155.
8. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001;60:741-747. (Pubitemid 32678918)
9. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:110-118. (Pubitemid 34701218)